Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

Stacy Loeb, MD
Published: Wednesday, Oct 11, 2017



Stacy Loeb, MD, assistant professor of Urology and Population Health at NYU Langone Health's Perlmutter Cancer Center, discusses the impact of different genomic tests for patients with prostate cancer.

Patients now have more testing options than before, states Loeb. Patients no longer need to rely on a single biopsy, as there are multiple tests which will help physicians determine the most beneficial treatment and management options for the patient.
 


Stacy Loeb, MD, assistant professor of Urology and Population Health at NYU Langone Health's Perlmutter Cancer Center, discusses the impact of different genomic tests for patients with prostate cancer.

Patients now have more testing options than before, states Loeb. Patients no longer need to rely on a single biopsy, as there are multiple tests which will help physicians determine the most beneficial treatment and management options for the patient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x